Team
Jon Amund Eriksen, MSc
Chief Executive Officer
Founder of Hubro Therapeutics with extensive industrial R&D experience from leadership positions at several biotech and pharmaceutical companies. With more than 40 years R&D experience and 35 years within the field of cancer immunotherapy and is inventor and co-inventor of several patents. Co-founder of Gemvax AS, Targovax ASA and Hubro Therapeutics AS. Mr. Eriksen is educated as a chemist (MSc) from the University of Oslo, Norway.
Sarah J. Arbe-Barnes, PhD
Chief Drug Development Officer
With over 30 years of biotech and consulting experience in a range of leadership roles and therapeutic areas Dr Sarah Arbe-Barnes, with a PhD in Biochemistry from the University of Bath, UK, has led multiple global product development programmes.
Robert M. Miller, MD
Chief Medical Officer
Dr Robert Miller, with 33 years R&D experience particularly in oncology including cancer immunotherapy, is a Physician with a license to practice with degrees from the University of London, the Royal College of Surgeons and is a Fellow of the Faculty of Pharmaceutical Medicine.
Henrik K Eriksen, MSc
Director Technology and IP
Mr. Kvalheim Eriksen has 5 years of R&D experience within the field of immunotherapy of cancer from Hubro Therapeutics AS. With his background from molecular biology and microbiology, he has contributed to the development of the company’s technology platforms and is co-inventor of patent applications. Mr. Kvalheim Eriksen holds a MSc in molecular biology from the University of Oslo, Norway.
Board of Directors
Jon Amund Eriksen, MSc
Chairman of the Board of Directors
Founder of Hubro Therapeutics with extensive industrial R&D experience from leadership positions at several biotech and pharmaceutical companies. 30 years of R&D experience within the field of cancer immunotherapy and is inventor and co-inventor of several patents.
Co-founder of Gemvax AS, Targovax ASA and HUbro Therapeutics AS. Mr. Eriksen is educated as a chemist (MSc) from the University of Oslo, Norway.
Tom A. Thorsen
Deputy Chairman of The Board of Directors
Mr. Thorsen is the CEO at Algot Invest AS. Following two and a half decades of executive management, board level roles and investments, Mr. Thorsen is a seasoned investor with extensive experience in commercialization, M&A processes and acting as a dealmaker, board member and owner in several successful companies.
Mr. Thorsen was previously a board member in Tantan, which was successfully sold to Momo (NASDAQ, China’s leading mobile networking platform) in February 2018. He has also held positions as board member in Targovax and OncoImmunity, the latter which was successfully sold in 2019 to Japanese NEC.